About Pudee

Reliability, Responsibility and Rapidity

Founded in 2007, focus on the synthesis of small molecule compounds and the extraction of some natural compounds. We develop, produce and sell high-quality advanced intermediates and some APIs with competitive prices.
Get Appointment

Contact Info

  • Building 2, Handa Science and Technology Park
    No. 8 Pioneer Road
    High-tech Zone. Suzhou.
  • 86 512 6803 2792
    86 512 6803 2791
  • willdyhan@pudeepharm.com
    sales@pudeepharm.com

Product Details

Alectinib Intermediate

Alectinib Intermediate | 1256579-06-2

Chemical Name: 9-Bromo-6,11-dihydro-8-hydroxy-6,6-dimethyl-11-oxo-5H-benzo[b]carbazole-3-carbonitrile

CAS Number: 1256579-06-2
Formula: C19H13BrN2O2
Molecular weight: 381.22

Product Description

"

Alectinib is an oral drug that blocks the activity of anaplastic lymphoma kinase (ALK) and is used to treat non-small-cell lung cancer (NSCLC). Alectinib was approved in Japan in July 2014 for the treatment of ALK fusion-gene positive, unresectable, advanced or recurrent non-small-cell lung cancer (NSCLC).

It was approved by the US Food and Drug Administration (FDA) in December 2015 to treat patients with advanced ALK-positive NSCLC whose disease worsened after, or who could not tolerate, treatment with crizotinib (Xalkori)

It got a conditional approval by the European Medicines Agency in February 2017 for the same indication. This means that additional studies are awaited to confirm a positive benefit-risk-ratio.

The material 9-Bromo-6,11-dihydro-8-hydroxy-6,6-dimethyl-11-oxo-5H-benzo[b]carbazole-3-carbonitrile(CAS Registry Number 1256579-06-2 ) is a key intermediate used for Alectinib.

"